Table 1 Baseline patient characteristics
Variables | TKI-naive group (n = 20) | IM-PD group (n = 30) | IM-PD/SU-treated group (n = 31) |
|---|---|---|---|
Age, years (range) | 54 (32–74) | 60 (32–76) | 50 (31–70) |
Sex | |||
Male | 15 (75.0%) | 18 (60.0%) | 19 (61.3%) |
Female | 5 (25.0%) | 12 (40.0%) | 12 (38.7%) |
Primary tumour site | |||
Stomach | 9 (45.0%) | 14 (46.7%) | 6 (19.4%) |
Small bowel | 11 (55.0%) | 16 (53.3%) | 24 (77.4%) |
Others | 0 | 0 | 1 (3.2%) |
Primary mutations | |||
KIT exon 11 | 13 (65.0%) | 20 (66.7%) | 23 (76.7%) |
KIT exon 9 | 4 (20.0%) | 4 (13.3%) | 4 (13.3%) |
PDGFRA exon 18 | 0 | 2 (6.7%) | 0 |
Wild type KIT/PDGFRA | 2 (10.0%) | 2 (6.7%) | 0 |
Not available | 1 (5.0%) | 2 (6.7%) | 3 (10.0%) |
Secondary mutations | N = 17 | N = 22 | |
KIT exon 13 | 3 (17.6%) | 3 (13.6%) | |
KIT exon 14 | 0 | 1 (4.5%) | |
KIT exon 17 | 6 (35.3%) | 9 (40.9%) | |
KIT exon 18 | 0 | 1 (4.5%) | |
